Lupin has signed a licensing agreement with NeuClone Pty Ltd for cell line technology to develop cancer treatment medicines
Drug maker Lupin has signed a licensing agreement with Sydney based private specialty life science company NeuClone Pty Ltd for cell line technology to develop cancer treatment medicines.
“Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in oncology to its partner,” Lupin said in a statement.
The agreement will also entail the Lupin Biological Research Programme scientific research staff to work with NeuClone teams at their facility as part of the overall technology transfer arrangements specified within the agreement, it added.
Cyrus Karkaria, president and head, Lupin Biological Research Programme, “The multi-billion dollar opportunity, with blockbuster biologics going off patent in the next 5-8 years, is something that Lupin is pursuing aggressively”.
“This exclusive licensing arrangement with NeuClone is a part of that strategy and would enable us to capitalise on cutting edge technology to address the biologicals market.”
He further said that such agreements coupled with the company’s own products pipeline will go a long way in helping it address the impending opportunity and develop a substantial differentiated biological pipeline.
The company currently has 6-8 products (proteins) in the pipeline and is looking to launch its first biological in the Indian market by the middle of 2011.
NeuClone CEO, Mr Noelle Sunstrom said: “This is an exciting time for NeuClone and our stakeholders as our investment in mammalian CHO cell lines is commercialised. In particular, we are enthusiastic about further developing the relationship with Lupin, an important global generic manufacturer.”
According to industry estimates, the market for biosimilars globally is pegged at over $100 billion, whereas the Indian market for biosimilars—including insulin, hormones, vaccines and plasma proteins—is valued at around Rs2,500 crore.
On Wednesday, Lupin ended 0.85% down at Rs465.85 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.57% to 18,608.81.
The device is priced at Rs5,999 and is available across Tata DOCOMO and Tata Photon stores
Tata DOCOMO, the GSM brand of Tata Teleservices, has launched an Internet access device—3G Wi-Fi Hub—enabling multiple users and devices to share wireless Internet access and stay connected on the go. The device offers uninterrupted connectivity for specific Wi-Fi devices like laptops, tablets, gaming consoles and Wi-Fi-enabled televisions.
The device enables users to manoeuvre between Tata DOCOMO’s Next-Gen 3G GSM network and Tata Photon Plus on the CDMA platform—one technology at a time—offering speeds of up to 7.2 Mbps. It allows users to access the Internet at 3G speeds in all the nine Tata DOCOMO circles where the company has the license, while allowing them to seamlessly switch to the high-speed Tata Photon Plus platform in other locations.
The device offers speed up to 7.2 Mbps in the 3G mode, and up to 3.1Mbps in the High-Speed Internet Access (HSIA) mode. Apart from a portable powered battery, seamless connectivity, simple browser-based configuration, the device is also password-protected for greater security.
The device works on both the 3G and Photon (CDMA) platforms, depending on the SIM inserted. There are two plans available—the Wi-Fi Rs750 and Wi-Fi Rs1,000 plans. The Wi-Fi Rs750 Plan comes with a monthly rental of Rs750, wherein customers can enjoy data usage of 2GB. Post the 2 GB being consumed, customers will have to pay a nominal cost of 50 paise per MB for additional data usage. Similarly, the Wi-Fi Unlimited Rs1,000 Plan comes with a monthly rental of Rs1,000, wherein customers will get 5GB of data usage. The device offers speeds of up to 7.2 Mbps in the 3G mode, while the Photon platform offers speeds of up to 3.1 Mbps. The device is priced at Rs5,999 and is available across Tata DOCOMO and Tata Photon stores.
Aptech recommended a dividend of 25% on the face value of equity shares
Aptech, the global career education and training company, said that its net profit for the financial year ended 31 March 2011 stood at Rs44.97 crore compared to a loss of Rs22.35 crore in FY09-10.
During the same period, the company’s operating income was Rs190.75 crore against Rs157.64 crore in the previous financial year, representing a growth of 21.0%
Ninad Karpe, managing director & CEO, Aptech said, “In the recent years, the demand for career education and specialised courses has been steadily on the rise due to the growing emphasis on professional and skill-based knowledge. The year gone by has seen us consolidate our position as a global education & training services company having reached over 40 countries with over 1300 centres till now.
The company recommended a dividend of 25% on the face value of equity shares.
On Wednesday, Aptech ended 4.33% up at Rs101.25 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.57% to 18,608.81.